Table 2. Demographic and Clinical Characteristics of Final Cohort.
| Characteristic | No. (%) (N = 35 375) |
|---|---|
| Age at initial diagnosis, median (IQR), y | 66.7 (58.4-74.1) |
| Sex | |
| Women | 18 756 (53.0) |
| Men | 16 613 (47.0) |
| Unknown | 6 (0.02) |
| Race/ethnicity | |
| White | 30 140 (85.2) |
| Black | 1040 (2.9) |
| Asian | 857 (2.4) |
| Hispanic | 323 (0.9) |
| Other | 267 (0.8) |
| Unknown | 2748 (7.8) |
| Smoking status | |
| Smoker | 32 650 (92.3) |
| Nonsmoker | 2725 (7.7) |
| Histologic type | |
| Completeness | 30 813 (87.1) |
| Adenocarcinoma | 18 331 (59.5) |
| Squamous cell carcinoma | 5816 (18.9) |
| NSCLC unspecified | 3601 (11.7) |
| Small cell lung cancer | 3065 (9.9) |
| Stage | |
| Completeness | 26 843 (75.9) |
| 1 | 7083 (26.4) |
| 2 | 3069 (11.4) |
| 3 | 5889 (21.9) |
| 4 | 8495 (31.6) |
| Limited | 1222 (4.6) |
| Extensive | 1085 (4.0) |
| Treatment received within MGB health care systema | |
| Surgical treatment | 13 628 (38.5) |
| Chemotherapy | 14 039 (39.7) |
| Radiation therapy | 14 710 (41.6) |
| Target therapy | 2631 (7.4) |
| Immunotherapy | 504 (1.4) |
| EGFR testedb | 4655 (13.1) |
| EGFR status | |
| Variant positive | 857 (18.4) |
| Variant negative | 3798 (81.6) |
| KRAS testedb | 4655 (13.1) |
| KRAS status | |
| Variant positive | 1242 (26.7) |
| Variant negative | 3413 (73.3) |
| BRAF testedb | 4655 (13.1) |
| KRAF status | |
| Variant positive | 171 (3.7) |
| Variant negative | 4484 (96.3) |
| ALK testedc | 3791 (10.1) |
| ALK status | |
| Rearrangement present | 203 (5.4) |
| Rearrangement not present | 3588 (81.6) |
| ROS testedc | 2436 (6.9) |
| ROS status | |
| Rearrangement present | 51 (2.1) |
| Rearrangement not present | 2385 (97.9) |
| Follow-up from initial diagnosis, median (IQR), y | 1.62 (0.63-4.14) |
Abbreviations: IQR, interquartile range; MGB, Mass General Brigham; NSCLC, non–small cell lung cancer.
a
Patients received treatments within the MGB health care system with International Classification of Diseases, Ninth Revision (ICD-9) or International Statistical Classification of Diseases and Related Health Problems, Tenth Revision (ICD-10) codes, procedure codes, or medication codes available.
b
EGFR, KRAS, and BRAF were tested using the SNaPshot assay (Thermo Fisher Scientific).
c
ALK and ROS were tested using fluorescence in situ hybridization or immunohistochemistry.